{"id":753005,"date":"2023-05-01T08:51:03","date_gmt":"2023-05-01T12:51:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-announces-release-of-inaugural-esg-report\/"},"modified":"2023-05-01T08:51:03","modified_gmt":"2023-05-01T12:51:03","slug":"catalyst-pharmaceuticals-announces-release-of-inaugural-esg-report","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/catalyst-pharmaceuticals-announces-release-of-inaugural-esg-report\/","title":{"rendered":"Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report"},"content":{"rendered":"
\n

CORAL GABLES, Fla., May 01, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases today announced the release of its inaugural Environmental, Social, and Governance Report (“ESG Report”). The inaugural ESG Report provides stakeholders with transparency on the Company’s practices across issues within the ESG field, such as sustainability and equity, and details how Catalyst navigates key issues to its mission, such as ensuring patients have access to safe and affordable medicine.<\/p>\n

“Since Catalyst was founded over 20 years ago, we have operated with our mission fully embedded into our core strategy \u2013 to improve the lives of those who suffer from rare diseases. As we grow and evolve, expanding our reach and patient value proposition, it is imperative that Catalyst continues to act responsibly and hold itself accountable,”\u00a0stated Patrick J. McEnany, Chairman and CEO of Catalyst. “We are proud to share our inaugural ESG Report, which highlights our ESG strategy, key areas of focus, and the meaningful progress we are making in each. Further, it contextualizes the evolution of our ESG journey and outlines how we will continue to operate responsibly as we pursue growth initiatives and maintain our commitment to the patient community we serve. We look forward to sharing further progress on our ESG program strategy in future reporting periods as we deliver against our strategic priorities and create value for our stakeholders.”\u00a0<\/p>\n

The report highlights Catalyst’s commitment to drive sustainable and collective value across a variety of topics determined to be most impactful and material to its business by key stakeholders. The Company has aligned its ESG Report with multiple reporting frameworks, including the Sustainability Accounting Standards Board (“SASB”), the Global Reporting Initiative (“GRI”), and the United Nations’ Sustainable Development Goals (“UN SDGs”).<\/p>\n

\n 2022 ESG Program Highlights<\/strong>\n <\/p>\n